Acromegaly and Coronary Disease: An Integrated Evaluation of Conventional Coronary Risk Factors and Coronary Calcifications Detected by Computed Tomography

Author:

Cannavo Salvatore1,Almoto Barbara1,Cavalli Giovanni2,Squadrito Stefano1,Romanello Giovanni1,Vigo Maria Teresa1,Fiumara Francesco3,Benvenga Salvatore1,Trimarchi Francesco1

Affiliation:

1. Sezione di Endocrinologia (S.C., B.A., S.S., G.R., M.T.V., S.B., F.T.) 98125 Messina, Italy

2. e Unità Coronarica (G.C.), Dipartimento Clinico Sperimentale di Medicina e Farmacologia, University of Messina, 98125 Messina, Italy

3. Centro di Diagnostica per Immagini (F.F.), Santa Teresa di Riva, 98028 Messina, Italy

Abstract

Abstract Context: Coronary atherosclerosis in acromegaly was not extensively investigated in the literature until now. At autopsy, it was demonstrated in about 20% of patients with long-lasting disease, and myocardial infarction was reported as cause of death in a quarter of acromegalics. Objective: The objective of the study was to evaluate coronary atherosclerosis in a cohort of acromegalics with controlled or uncontrolled disease. Design: Coronary risk was evaluated by the Framingham algorithm, according to the Framingham score (FS). Patients were stratified into low (<6%), intermediate (6–20%), and high (>20%) midterm risk. Coronary calcium deposits were detected by multidetector computed tomography and measured by the Agatston algorithm. Coronary artery calcium [Agatston score (AS)] was quantified at the level of left main artery, left anterior descendent artery, left circumflex artery, right coronary artery, and posterior descendent artery. Total AS values in healthy persons are less than 50 (aged < 60 yr) and less than 300 (age ≥ 60 yr). Patients: Thirty-nine patients (12 males and 27 females, aged 53.0 ± 2.1 yr) were evaluated. In each patient, the mean of at least four determinations of serum IGF-I, assayed during the last 2 yr before study, was normalized for the age-matched normal range, and the result was presented as sd value (IGF-I sd). On the basis of serum IGF-I sd, acromegaly was considered controlled (≤1.9 sd; n = 24) or uncontrolled (≥ 2.0 sd; n = 15). Results: The FS was intermediate in 12 and high in two acromegalics. Overall, the FS was not correlated with serum GH values and IGF-I sd. Mean FS was not significantly different between patients with controlled and uncontrolled acromegaly. Total AS was increased in nine patients, most frequently in left anterior descendent, left circumflex, and left main arteries. In these nine patients, mean AS was similar in individuals with controlled and those with uncontrolled acromegaly, and the rate of 17% patients with controlled disease having increased AS was not statistically different from the rate of 33% uncontrolled acromegalics. Total AS was increased in six of 12 males and in three of 27 females (χ2 7.1, P < 0.01). Overall, total AS correlated with FS (r2 = 0.4, P < 0.0002) but not age, body mass index, disease duration, indexed left ventricular mass, serum cholesterol, triglycerides, GH, or IGF-I levels. Increased AS was more frequently observed in acromegalics with diabetes mellitus (χ2 = 5.2, P < 0.05) or hypertension (χ2 = 9.8, P < 0.002) but not in smokers (χ2 = 1.34, P = NS). Seven of nine patients with coronary calcium deposits had a FS greater than 6%. In six of 13 patients with FS greater than 6%, multidetector computed tomography did not demonstrate coronary calcifications. Conclusions: In our study, the integrated evaluation of FS and AS showed that 41% of acromegalics are at risk for coronary atherosclerosis and that coronary calcifications were evident in about half of them despite the fact that myocardial infarction was not more frequent in acromegalic patients than the general population. Moreover, the control of acromegaly did not influence significantly the extent of coronary atherosclerosis.

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference21 articles.

1. Acromegaly;Melmed;N Engl J Med,1990

2. Mortality and cancer incidence in acromegaly: a retrospective cohort study;Orme;J Clin Endocrinol Metab,1998

3. Effect of six months treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly;Colao;Eur J Endocrinol,2002

4. Characterisation of premature atherosclerosis of carotid arteries in acromegalic patients;Otsuki;Clin Endocrinol (Oxf),2001

5. Systemic complications of acromegaly: epidemiology, pathogenesis, and management;Colao;Endocr Rev,2004

Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Growth Hormone Excess: Implications and Management;Endocrine, Metabolic & Immune Disorders - Drug Targets;2023-05

2. Classic endocrine disorders: implications for cardiovascular disease;Cardiovascular Endocrinology and Metabolism;2023

3. Association of Epicardial Adipose Tissue Thickness with Cardiovascular Risk in Acromegaly;Medeniyet Medical Journal;2022-06-23

4. (Cardiovascular complications in acromegaly);Cor et Vasa;2022-02-22

5. Acromegaly;Pituitary Adenomas;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3